Hummingbird Bioscience

Warm congratulations to the Endeavor BioMedicines team for the Series C financing. We are excited to see ENV-501's (previously HMBD-501) planned entry to the clinic later this year. Read more on Fierce Biotech: https://bit.ly/3WfJJdW

Register for the SCRI Clinical Trials Symposium 2024 (30-31 July)! https://bit.ly/3xIprzF Kon Yew Kwek, BMBCh, DPhil, Senior Vice President of Clinical Development at Hummingbird Bioscience will share our clinical development strategy and progress. 31 July 2024 (Day 2) Time: 11 am – 12.30 pm Organized by the Singapore Clinical Research Institute (SCRI), the two-day event aims to showcase the impact of and opportunities for clinical trials in Singapore. #clinicaldevelopment #clinicaltrials #singapore

Piers Ingram, Chief Executive Officer of Hummingbird Bioscience is on The Medicine Maker 2024 Power List: https://bit.ly/49uPhV4 Since Hummingbird Bio's inception, Piers has scaled the company's capabilities and led the team to conceptualize and build two oncology antibody therapeutics in-house that are now in clinical development. Recognizing the potential for ADCs with a better safety-efficacy profile, he led the team to design a HER3-ADC that was recently out-licensed to Endeavor BioMedicines. 

We are delighted to share that Piers Ingram, Chief Executive Officer of Hummingbird Bioscience, has been recognized on The Medicine Maker 2024 Power List, which celebrates influential leaders in biopharma. Read more about the recognition here: https://bit.ly/49uPhV4

The Hummingbird Bioscience team is at the American Association for Cancer Research Meeting 2024 over the next few days presenting our HMBD-001 and HMBD-002 posters. If you are at #AACR, visit us to learn more and catch up on our latest developments. Piers Ingram Jerome Boyd-Kirkup Angele Maki Bhushan Dharmadhikari, PhD

Don't miss the 3rd Annual VISTA Symposium TOMORROW, March 27th at 11:00am ET. Register here: https://lnkd.in/eNiGhGWc #VISTA #oncology #immunotherapy #cancer

This year’s virtual VISTA symposium, co-hosted by Hummingbird Bioscience, will see Bhushan Dharmadhikari, PhD, Principal Scientist, and Jerome Boyd-Kirkup, Chief Scientific Officer, presenting insights on targeting VISTA and a clinical development update for HMBD-002, our anti-VISTA antibody therapy, respectively.   Register at https://bit.ly/48poLfg to learn more about the team’s work in #VISTA biology and HMBD-002 #clinicaldevelopment. 

Excited to reflect on my recent presentation at the Clinical Trial Festival organized by Sarmila Silvaraja at IMAPAC where I had the privilege to discuss the intricacies of precision oncology clinical trials and the clinical research landscape in the Asia-Pacific region. It was an exceptional platform to underscore the innovative strides we are making at Hummingbird Bioscience in the field of targeted therapies. At Hummingbird Bioscience we are deeply committed to pioneering advancements in the field of oncology. We're at the forefront of designing therapies that are not just innovative but are tailored to meet the unique needs of cancer patients. #CTFA2024 #PrecisionOncology #ClinicalResearch #InnovationInCancerCare #HummingbirdBioscience #OncologyClinicalTrials

This is the third year that Hummingbird Bioscience has collaborated with South West Community Development Council and People's Association to give back to the community. On 23rd and 24th February 2024, our CSR committee and volunteers packed and distributed bags of food and necessities to households in Telok Blangah. We hope that our contributions have made a positive impact on the community.  The initiative is part of a larger program (Adopt @ South West) by the South West CDC, to provide well-rounded assistance in the areas of social support & wellness, education & enrichment, and home maintenance & improvement.

One week to this year's VISTA Symposium! Register at https://bit.ly/48poLfg to learn about the latest insights in VISTA biology and the ongoing clinical development of anti-VISTA therapies.